ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
22.91
+0.10 (0.44%)
Jun 27, 2025, 4:00 PM - Market closed

ArriVent BioPharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
17.0915.39.716.473.02
Research & Development
83.327964.8830.438.58
Operating Expenses
100.4194.3174.5936.9111.59
Operating Income
-100.41-94.31-74.59-36.91-11.59
Interest & Investment Income
12.9513.825.26--
EBT Excluding Unusual Items
-87.46-80.49-69.33-36.91-11.59
Pretax Income
-127.46-80.49-69.33-36.91-68.81
Net Income
-127.46-80.49-69.33-36.91-68.81
Net Income to Common
-127.46-80.49-69.33-36.91-68.81
Shares Outstanding (Basic)
3431211
Shares Outstanding (Diluted)
3431211
Shares Change (YoY)
316.83%1369.88%67.64%79.57%-
EPS (Basic)
-3.78-2.56-32.38-28.90-96.75
EPS (Diluted)
-3.78-2.56-32.38-28.90-96.75
EBIT
-100.41-94.31-74.59-36.91-11.59
Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q